within Pharmacolibrary.Drugs.ATC.N;

model N07XX01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.4999999999999998e-06,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0009,
    k12             = 0.15,
    k21             = 0.15
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07XX01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tirilazad is a nonglucocorticoid 21-aminosteroid (lazaroid) that acts as a lipid peroxidation inhibitor. It was developed for neuroprotective use, particularly in the treatment of acute spinal cord injury and subarachnoid hemorrhage. However, it is not approved or in use today, as clinical trials failed to demonstrate sufficient efficacy.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for tirilazad in adult patients, based on published summary data from clinical trials and public reviews. Likely based on intravenous administration in the context of neuroprotection in acute injury patients.</p><h4>References</h4><ol><li><p>Wang, Y, et al., &amp; Higgins, MJ (1999). Venous irritation, pharmacokinetics, and tissue distribution of tirilazad in rats following intravenous administration of a novel supersaturated submicron lipid emulsion. <i>Pharmaceutical research</i> 16(6) 930–938. DOI:<a href=&quot;https://doi.org/10.1023/a:1018846607804&quot;>10.1023/a:1018846607804</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10397616/&quot;>https://pubmed.ncbi.nlm.nih.gov/10397616</a></p></li><li><p>Fleishaker, JC, et al., &amp; Peters, GR (1994). The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. <i>Clinical pharmacology and therapeutics</i> 56(4) 389–397. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1994.153&quot;>10.1038/clpt.1994.153</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7955800/&quot;>https://pubmed.ncbi.nlm.nih.gov/7955800</a></p></li><li><p>Fleishaker, JC, &amp; Peters, GR (1997). Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day. <i>International journal of clinical pharmacology and therapeutics</i> 35(1) 28–32. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9021439/&quot;>https://pubmed.ncbi.nlm.nih.gov/9021439</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07XX01;
